Core Viewpoint - The announcement by健世科技-B (09877.HK) highlights the results of several clinical trials related to their cardiovascular systems, showcasing advancements in minimally invasive heart valve procedures [1] Group 1: Clinical Trial Results - The global multicenter clinical trial "TRINITY" for the LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) system has reported six-month follow-up results [1] - The one-year follow-up results for the JensClip transcatheter mitral valve repair (TMVr) system and its application in challenging cases were presented [1] - The one-year follow-up results for the Ken-Valve transcatheter aortic valve replacement (TAVR) system and its performance in challenging cases were also shared [1] Group 2: Event Details - The results were presented at the TCT 2025 conference held in San Francisco, USA [1]

Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 自願公告 公司多產品組合LuX-Valve Plus TRINITY研 究、JensClip及 Ken-Valve臨床效果於美國TCT 2025發佈的更新 茲提述本公司日期為二零二五年十月二十八日的公告（「十月二十八日公告」）。 本公告乃由寧波健世科技股份有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本 集 團」）按 自 願 基 準 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 十 月 二 十 八 日 公 告 的 最 新 資 料，該 公 告 內 容 已 於 本 公 告 重 述，其 中 有 關 安 全 性 結 果 的 最 新 ...

Core Viewpoint - The announcement highlights the results of various clinical trials for LuX-Valve Plus, JensClip, and Ken-Valve, showcasing advancements in transcatheter heart valve technologies presented at the TCT2025 conference [1] Group 1: Clinical Trial Results - LuX-Valve Plus's global multicenter clinical trial (TRINITY) reported six-month follow-up results for transcatheter tricuspid valve replacement (TTVR) [1] - JensClip's one-year follow-up results for transcatheter mitral valve repair (TMVr) were shared, along with evidence of its effectiveness in challenging cases [1] - Ken-Valve's one-year follow-up results for transcatheter aortic valve replacement (TAVR) were also presented, including outcomes in challenging case applications [1] Group 2: Conference Presentation - The results were presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT2025) conference held in San Francisco [1]

Core Viewpoint - The announcement highlights the results of multiple clinical trials for various cardiovascular systems developed by the company, showcasing advancements in minimally invasive heart valve procedures [1] Group 1: Clinical Trial Results - The TRINITY trial results for the LuX-Valve Plus system, focusing on transcatheter tricuspid valve replacement (TTVR), were presented, emphasizing the six-month follow-up outcomes [1] - The one-year follow-up results for the JensClip system, which is designed for transcatheter mitral valve repair (TMVr), were also shared, along with insights on challenging case applications [1] - Additionally, the one-year follow-up results for the Ken-Valve system, used for transcatheter aortic valve replacement (TAVR), were discussed, including its performance in challenging cases [1] Group 2: Event Details - The results were presented at the TCT 2025 conference held in San Francisco, indicating the company's active participation in significant cardiovascular academic events [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 自願公告 TRINITY是 一 項 全 球 前 瞻 性、多 中 心、單 臂 臨 床 試 驗，主 要 用 於 評 估LuX-Valve Plus於 重 度 三 尖 瓣 反 流 及 外 科 高 危 患 者 中 應 用 的 安 全 性 及 有 效 性。該 項 研 究 共 納入全球20家中心的161例 患 者，其 中18家 中 心 來 自 法 國、德 國、西 班 牙、丹 麥 及 英 國，患 者 平 均 年 齡 為77歲。 – 1 – 本 次 臨 床 研 究 結 果 顯 示： (1) 器械成功率約為97%；及 (2) 平均器械操作時間為41.60±19.62分鐘，其 ...

二零二五年股東特別大會的出席情況 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Jenscare Scientific Co., Ltd. 寧波健世科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：9877） 二零二五年第二次股東特別大會 投票表決結果 茲提述寧波健世科技股份有限公司（「本公司」）日期為二零二五年九月二十六 日的通函（「通 函」），當 中 載 有（其 中 包 括）本公司二零二五年第二次股東特別大 會（「二零二五年第二次股東特別大會」）通 告。除 另 有 所 指 外，本 公 告 所 用 詞 彙 與 通 函 所 界 定 者 具 有 相 同 涵 義。 由於上述第1項 特 別 決 議 案 獲 三 分 之 二 以 上 票 數 贊 成，於 二 零 二 五 年 第 二 次 股 東特別大會上提呈的決議案作為本公司特別決議案獲股東 ...

Core Viewpoint - Jenscare Scientific's product LuX-Valve Plus has been approved for commercialization in designated medical institutions in the Greater Bay Area, which is expected to enhance the company's market penetration and revenue growth [1] Group 1: Company Developments - Jenscare Scientific's LuX-Valve Plus has received approval to enter the Hong Kong and Macau Medical Device Directory, allowing its use in mainland China [1] - The approval is part of the "Hong Kong and Macau Medical Device Pass" policy aimed at facilitating the use of urgently needed medical devices in the Greater Bay Area [1] - The company plans to leverage this policy opportunity to accelerate the commercialization of LuX-Valve Plus and address unmet clinical needs [1] Group 2: Market Context - The "Hong Kong and Macau Medical Device Pass" policy is designed to provide a more efficient access channel for innovative medical devices in the Greater Bay Area [1] - This initiative aims to meet patients' urgent demand for advanced medical technologies and offer diverse treatment options [1] - The company anticipates that the experience gained from this initiative will support its future expansion in domestic and international markets [1]

Core Viewpoint - Jenscare Scientific's product LuX-Valve Plus has been approved for commercialization in the Greater Bay Area, enhancing the company's market penetration and growth potential [1] Group 1: Company Developments - Jenscare Scientific (Netherlands) B.V. has received approval for its LuX-Valve Plus product to enter the Hong Kong and Macau medical device directory [1] - The approval allows for commercial clinical use in designated medical institutions within the Greater Bay Area [1] - The company aims to leverage the "Hong Kong and Macau Medical Device Pass" policy to accelerate the market penetration of LuX-Valve Plus [1] Group 2: Industry Context - The "Hong Kong and Macau Medical Device Pass" is a medical innovation policy implemented in the Guangdong-Hong Kong-Macao Greater Bay Area [1] - This policy facilitates the use of urgently needed drugs or medical devices in mainland clinical settings after approval, addressing patient needs for advanced medical technologies [1] - The initiative aims to provide diverse treatment options for patients and create an efficient access channel for innovative medical devices [1]

Core Viewpoint - Jenscare Scientific (Netherlands) B.V., a wholly-owned subsidiary of Jian Shi Technology-B (09877), has received approval for its product LuX-Valve Plus to enter the Hong Kong and Macau medical device market, enabling commercial clinical use in designated medical institutions within the Greater Bay Area [1] Group 1: Product Approval and Market Entry - LuX-Valve Plus has successfully passed the "Hong Kong and Macau Medical Device Pass" approval due to its extensive successful clinical application experience across major regions including Asia-Pacific, North America, Europe, South America, and the Middle East [1] - The product is expected to address the urgent treatment needs of numerous patients suffering from tricuspid regurgitation in the Greater Bay Area [1] Group 2: Strategic Plans and Market Expansion - The company aims to leverage the "Hong Kong and Macau Medical Device Pass" policy opportunity to actively promote the commercialization of LuX-Valve Plus in the Greater Bay Area, accelerating market penetration [1] - This initiative is expected to help the company accumulate critical experience for further expansion into domestic and overseas markets, driving long-term sustainable revenue growth [1]

Core Viewpoint - The approval of LuX-Valve Plus for commercial clinical use in the Greater Bay Area marks a significant advancement in addressing the unmet clinical needs of patients with severe tricuspid regurgitation, particularly in high-risk surgical cases [1][2] Group 1: Product Approval and Market Entry - Jenscare Scientific's LuX-Valve Plus has been officially approved to enter the Hong Kong-Macao Medical Device Directory, allowing its use in designated medical institutions in the Greater Bay Area [1] - The "Hong Kong-Macao Medical Device Pass" policy aims to facilitate the entry of urgently needed medical devices and drugs into the mainland, enhancing patient access to advanced medical technologies [1] Group 2: Product Features and Clinical Performance - LuX-Valve Plus is designed specifically for patients with severe tricuspid regurgitation and complex anatomical structures, offering a solution where few effective treatments exist [2] - The product features innovative design elements such as inter-ventricular anchoring and adaptive anti-leak rings, available in seven sizes from 40mm to 70mm, demonstrating excellent clinical performance and safety [2] Group 3: Strategic Market Expansion - The company plans to leverage the "Hong Kong-Macao Medical Device Pass" policy to accelerate the commercialization of LuX-Valve Plus in the Greater Bay Area, aiming to meet the significant clinical demand [2] - Successful implantation and follow-up results globally have established LuX-Valve Plus's clinical value and advanced technology, which will support the company's long-term revenue growth and market expansion [2]